Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
Nature Medicine|May 3, 2016
Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteinsStanley Chun-Wei Lee, Heidi Dvinge, Eunhee Kim, et al.
NPJ Precision Oncology|February 26, 2024
Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patientsDamien Vasseur, Ahmadreza Arbab, Fabiola Giudici, et al.
Blood|April 21, 2021
Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA studyMatthieu Duchmann, Jean-Baptiste Micol, Nicolas Duployez, et al.
Journal of Cellular and Molecular Medicine|September 7, 2021
Myeloid malignancies with translocation t(4;12)(q11-13;p13): molecular landscape, clonal hierarchy and clinical outcomesVincent Parinet, Elise Chapiro, Audrey Bidet, et al.
Cells|June 24, 2022
Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved TestDamien Vasseur, Hela Sassi, Arnaud Bayle, et al.
Leukemia|April 21, 2023
UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemiaNicolas Duployez, Loïc Vasseur, Rathana Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2013
Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association groupMaxime Janin, Elena Mylonas, Véronique Saada, et al.
Blood Cancer Journal|April 17, 2025
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patientsChristophe Willekens, Alexandre Bazinet, Samy Chraibi, et al.
Blood Advances|October 25, 2024
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OSThomas Cluzeau, Fabio Guolo, Edmond Chiche, et al.
Nature Cancer|February 5, 2022
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohortLaurence Albiges, Stéphanie Foulon, Arnaud Bayle, et al.
Pageof 7